A 54-year-old woman presented to the emergency department with sudden-onset right-sided pleuritic chest pain with associated shortness of breath. Her past medical history consisted of autoimmune thyroiditis, previous pancreatitis and a complex vascular history requiring several interventions. The patient's chronic lower limb varicosities were treated with a long saphenous vein laser ablation and foam sclerotherapy. Her chronic pelvic pain associated with pelvic congestion syndrome had been managed with an ovarian iliac vein embolisation in 2014, which was repeated in 2019 due to persistent reflux through the original coils.

On presentation the patient was tachycardic with a heart rate of 100 BPM, otherwise her observations were unremarkable. A chest X-ray and CT pulmonary angiogram (CTPA) were ordered to investigate primarily for a pulmonary embolism as well as for other differentials of her presentation, such as pneumothoraces and pneumonias.

The chest X-ray (Figure 1) showed an 11 mm metallic ring opacity overlying the ventricles, this was at first queried as an artefact. Further examination of the patient revealed no overlying jewellery or clothing that could explain the radiological appearance. A lateral X-ray (Figure 2) confirmed the presence of the metallic ring in the right ventricle.

A CTPA (Figures 3, 4 and 5) showed that there was no pulmonary embolus or right heart strain, and confirmed the presence of an 11 mm metallic foreign body at the tip of the right ventricle, which was suspected to be a migrated pelvic vein embolisation (PVE) coil. On further investigation, the coil had been present on a previous CT of the abdomen and pelvis that had been requested for severe abdominal pain in 2016, but its presence had not been discussed in the radiologist’s report. The position of the coil had remained stable.

The patient was referred to the cardiac surgeons, who performed a bedside echocardiogram and found that the coil had endothelialised into the cardiac septum. The foreign body was considered to be a low risk for thrombus, and therefore no intervention or anticoagulation was required. ECG showed a normal sinus rhythm, and blood tests including troponin were unremarkable. The chest pain was deemed to be musculoskeletal in nature given that no acute cause was identified.

The patient was discharged and her case discussed in the vascular multidisciplinary meeting, which concluded that there was no interval change in appearance of the migrated coil, and therefore it was unlikely to be the cause of the patient’s symptoms. Similarly, an outpatient cardiology review concluded that the coil was both unlikely to be the cause of the patient’s symptoms or to result in future complications.

Discussion
Chronic pelvic pain is a complex condition that can be the result of gynaecological diseases, such as pelvic inflammatory disease,
endometriosis and fibroids. Alternatively, referred pain, psychological factors and venous incompetence are known to also contribute. In up to 60% of patients no definitive aetiology for chronic pelvic pain is identified.\(^1\) Pelvic venous congestion (PVC) is a cause of persistent non-cyclic chronic pelvic pain, typically as the result of ovarian vein incompetence resulting in pelvic varicosities. The pain is often exacerbated by standing and intercourse. Multiparous and premenopausal women are at greater risk of developing PVC and its prevalence is in the range of \(15–30\%\).\(^1\) PVC can be managed conservatively with analgesia, through surgical ligation or alternatively with interventional PVE.

PVE has been shown to be an effective treatment in women with chronic pelvic pain resulting from pelvic venous disorders.\(^1\) The embolic agents used can vary between coils, glue, vascular plugs, foam and liquid sclerosants, with some clinicians advocating the combined use of coils and sclerosing agents. Current clinical evidence is insufficient to compare the outcomes between the use of coils alone and in combination.\(^1\) Arterial percutaneous embolisation with coils was first used effectively in 1975, and in 1993 Edwards et al. documented the first use of coil embolisation in the management of PVC.\(^5\) PVE has been found to be efficacious in the management of PVC, with improvement in symptoms seen in 70–90% of patients.\(^3,6\)

The complications associated with PVE include bleeding, venous perforation and coil migration. Coil migration can be an immediate or delayed complication. Common migration sites include the pulmonary vasculature and the heart. Several studies have investigated the effectiveness of PVE in pelvic congestion syndrome and identified the risks of coil displacement. Kwon et al. demonstrated an 82% reduction in pain in 67 patients, but a 3% risk of coil embolization.\(^7\) Similarly, Ratnam et al. found a 1.4% risk of coil migration in 218 patients undergoing PVE.\(^1,8\) A systematic review of the effectiveness PVE in 1,308 patients across 22 studies reported a substantial early improvement in pain in approximately 75% of patients and a coil migration risk of <2%.\(^9\)

Interestingly, in the present case, the migrated coil was an incidental finding in a symptomatic patient and may not have been discovered had the patient not presented to the emergency department with chest pain. The stable appearance and asymptomatic nature of the migrated coil in the 4 year interval between the CT of the abdomen and pelvis in 2016 and the CTPA in 2020 mean that the chest pain is unlikely to be related to the coil. This raises the possibility that asymptomatic migrated coils may go underreported following PVE. The current coil migration rates in the literature relate predominantly to symptomatic patients or those presenting with complications in which investigations have noted a migrated coil. Thus, many patients who have had PVE may have migrated coils after the procedure, and the absence of associated symptoms mean that the migrated coils go undiscovered. Patients in
Coil Migration to the Right Ventricle Following Pelvic Vein Embolisation

this group could present at a later date with complications of coil migration, such as arrhythmias, thrombus, cardiac valve dysfunction or haemopericardium.\textsuperscript{2,3,10}

To the best of our knowledge, the underreporting of coil migration rates has not previously been discussed in the literature. Post-PVE screening at 6 weeks could help to prevent future complications of undetected migrated coils and improve the accuracy of documented migration rates. If true, underreporting also highlights the preoperative issue of incorrect complication rates being discussed when obtaining patient consent. The heart and pulmonary vasculature are common sites of migration. Therefore, a plain film chest radiograph, given the associated minimal radiation exposure to the patient, may be a sufficient screening tool for this purpose.

Coil migration following PVE has been well-reported in the literature, however, the management of displaced coils often differs between cases. In a similar respect to the present case, there are reports of coil migration to the right side of the heart both with and without methods of retrieval. Kyaw et al. outlined a case of coil migration to the right atrium immediately after a PVE procedure for pelvic congestion syndrome.\textsuperscript{10} Several unsuccessful percutaneous attempts were made at coil retrieval and thus their patient had to undergo an open thoracotomy in order for the coil to be removed from the damaged tricuspid valve.\textsuperscript{10} A further paper by Rastogi et al. discussed a case of coil migration following bilateral ovarian vein embolisation to the right ventricle.\textsuperscript{2} Their patient remained haemodynamically stable and asymptomatic throughout and it was decided that no further treatment was required.\textsuperscript{2}

In the present case, the patient had remained asymptomatic for several years after her PVE and the migrated coil was an incidental radiological finding. The endothelialised coil was believed to pose a low risk for thrombus and thus anticoagulation was not considered. Tonkin and Madden chose to anticoagulate in one of the three cases of coil migration they saw following PVE, advocating that anticoagulation should be considered only if there is an associated thrombus or an increased thrombotic risk due to position of the coil, for example within the valve apparatus.\textsuperscript{5}

To prevent complications of PVE, the importance of characterising the vessels prior to embolisation is highlighted in the literature. The type of vessel (artery or vein), the volume of blood flow through the target vessel and the size of the coil can all affect the likelihood of migration. To optimise stability, it is recommended that the coil should be greater than the diameter of the embolised vein. Yamasaki et al. suggest a coil size 30–50% greater than the target vessel, with alternative literature advocating the use of an exact coil size 1–3 mm greater than the diameter of the vessel.\textsuperscript{8,12–14} To prevent coil migration, we are reliant on the frictional resistance of the vessel and the radial force exerted by the coil and thus it is important to note the variable calibre of target veins.\textsuperscript{8,12–14} Typically, 0.035–0.038 inch coils are used with diameters ranging between 5 and 20 mm and lengths of 7–14 cm, and the number of coils deployed varies between clinicians.\textsuperscript{1,4,7}

To achieve permanent vessel occlusion the coils cause a mechanical obstruction, inducing thrombosis and eventual sclerosis of the target vessels.\textsuperscript{14} The choice of materials used to manufacture coils has progressed over time, primarily from stainless steel to platinum. Coils can be enlaced with fibres to increase their thrombogenic qualities, with materials such as PET and nylon enabling more rapid vessel occlusion and the use of fewer coils.\textsuperscript{1,15,16} Further technological advances have resulted in bioactive coils. Platinum coils can be coated with a hydrogel polymer that facilitates an increase in the coil’s thickness of up to fourfold its size when it comes into contact with blood or a liquid. Expansion of coils can result in more reliable vessel occlusion in the absence of effective coagulation.\textsuperscript{17,18} In addition to the material used to produce a coil, the configuration and transformation of a material from a primary to a tertiary structure helps to determine other qualities of the coil, such as stiffness, length and diameter.\textsuperscript{19}

Chest pain is one of the most common presenting complaints seen in the emergency department and it accounts for 25% of emergency medical admissions in England and Wales.\textsuperscript{20} The aetiology of chest pain can be characterised into cardiovascular causes (acute coronary syndromes,
Coil Migration to the Right Ventricle Following Pelvic Vein Embolisation

VASCULAR & ENDOVASCULAR REVIEW
Access at: www.VERjournal.com

1. Lopez AJ. Female pelvic vein embolization: indications, techniques, and outcomes. Cardiovasc Intervent Radiol. 2015;38:806–20. https://doi.org/10.1007/s00270-015-1074-7, PMID: 25804363.

2. Rastogi N, Kabulety NK, Kim D. Untethered coil migration into the right ventricle during the right ovarian vein coil embolization. Vasc Endovascular Surg. 2011;45:660–4. https://doi.org/10.1177/1538574411414924, PMID: 21757493.

3. Guerrero A, Theshpanous RK. A case report of a migrated pelvic coil causing pulmonary infarct in an adult female. Clin Pract Cases Emerg Med. 2020;4:436–9. https://doi.org/10.5811/cpcem.2020.5.47463, PMID: 32926706.

4. Gualro JA, Sánchez-Ballestín M, Sorre S, et al. A randomized trial of endovascular embolization treatment in pelvic congestion syndrome: fibered platinum coils versus vascular plugs with 1-year clinical outcomes. J Vasc Interv Radiol. 2018;29:45–53. https://doi.org/10.1016/j.jvir.2017.09.011, PMID: 29174618.

5. Edwards RD, Robertson IR, Maclean AB, Hemingway AP. Case report: pelvic pain syndrome – successful treatment of a case by ovarian vein embolization. Clin Radiol. 1993;47:429–31. https://doi.org/10.1016/0009-9260(93)80167-0, PMID: 851953.

6. Laborda A, Medrano J, Blass I, et al. Endovascular treatment of pelvic congestion syndrome: visual analog scale (VAS) long-term follow-up clinical evaluation in 202 patients. Cardiovasc Intervent Radiol. 2013;36:1066–34. https://doi.org/10.1007/s00270-013-0586-2, PMID: 23456353.

7. Kwon SH, Oh JH, Ko KR, et al. Transcatheter ovarian vein embolization using coils for the treatment of pelvic congestion syndrome. Cardiovasc Intervent Radioi. 2007;30:655–8. https://doi.org/10.1007/s00270-007-9040-7, PMID: 17458936.

8. Ratanjan LA, Marsh P, Holdstock JM, et al. Pelvic vein embolisation in the management of varicose veins. Cardiovasc Intervent Radiol. 2008;31:1559–64. https://doi.org/10.1007/s00270-008-9402-9, PMID: 18756371.

9. Daniels JF, Championer R, Shah L, et al. Effectiveness of embolization or sclerotherapy of pelvic veins for reducing chronic pelvic pain: a systematic review. J Vasc Interv Radiol. 2016;27:1487–86. https://doi.org/10.1016/j.jvir.2016.04.016, PMID: 27337639.

10. Kyew H, Park W, Rodriguez C, et al. Coil embolization to the right side of the heart after elective hypogastric vein embolization requiring open-heart surgery. Cath Lab Digest. 2018;26:9. https://www.cathlabdigest.com/article/coil-embolization-right-side-heart-after-elective-hypogastric-vein-embolization-requiring(accessed 25 May 2021).

11. Tonkin J, Madden B. From ovarian coils to pulmonary emboli. Am J Respir Crit Care Med. 2018;197:A3700.

12. Yamazaki W, Kizakura H, Ishikawa M, et al. Migration to the pulmonary artery of nine metallic coils placed in the internal iliac vein for treatment of giant rectal varices. Acta Radiol Short Rep. 2012;11:4–4. https://doi.org/10.10258/anr.2012020024, PMID: 23986845.

13. Nasser F, Cavalcante RN, Affonso BB, et al. Safety, efficacy, and prognostic factors in endovascular treatment of pelvic congestion syndrome. Int J Gyneco Obstet. 2014;125:65–8. https://doi.org/10.1016/j.ijgo.2013.10.008, PMID: 24486124.

14. Kuttinnen MG, Xie K, Jars A, et al. Pelvic venous insufficiency: imaging diagnosis, treatment approaches, and therapeutic issues. AJR Am J Roentgenol. 2015;204:448–58. https://doi.org/10.2214/AJR.14.12709, PMID: 26057669.

15. Terotola SO, Pessler GA, Premanand C. Nylon fibered versus non-fibered embolization coils: comparison in a swine model. J Vasc Interv Radiol. 2019;30:949–55. https://doi.org/10.1016/j.jvir.2018.10.004, PMID: 30935867.

16. Liebig T, Henkes H, Fischer S, et al. Fibered electrolytically detachable platinum coils used for the endovascular treatment of intracranial aneurysms. Initial experiences and mid-term results in 474 aneurysms. J Neurointerv Surg. 2014;10:5–26. https://doi.org/10.1177/17549462134909950100101, PMID: 20587260.

17. López-Benitiz R, Hallcscheidt P, Kraschel C, et al. Protective embolization of the gastrointestinal artery with a one-HydroCoil technique in radioembolization procedures. Cardiovasc Intervent Radiol. 2013;36:165–10. https://doi.org/10.1007/s00270-012-0381-9, PMID: 22448984.

18. Zander T, Medina S, Montes G, et al. Endoluminal occlusion devices: technology update. Med Devices Eur. 2014;7:425–36. https://doi.org/10.2214/AJR.14.12709, PMID: 24859252.

19. White JB, Ken CG, Cloft HJ, Kallmes DF. Coils in a nutshell: a review of coil physical properties. AJNR Am J Neuroradiol. 2008;29:942–4. https://doi.org/10.3174/ajnr.A1067, PMID: 18476005.

20. Kendall J, Hancock I. A review of coil physical properties. AJNR Am J Neuroradiol. 2018;29:942–4. https://doi.org/10.3174/ajnr.A1067, PMID: 18476005.

The present case illustrates how a migrated coil can remain asymptomatic for several years, and suggests that there may be underreporting of migration rates in the literature and discussion of inaccurate complication rates when obtaining patient consent for PVE. Screening following PVE may be a useful tool to identify migrated coils, improve the accuracy of coil migration rates and prevent late complications associated with migrated coils.